Search

Desoximetasone

A topical anti-inflammatory glucocorticoid used in dermatoses, skin allergies, psoriasis, etc.

Equine Botulinum Neurotoxin E Immune FAB2

Equine Botulinum Neurotoxin E Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype E. … It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes E in adults and pediatric patients.

Equine Botulinum Neurotoxin C Immune FAB2

It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes C in adults and pediatric patients.

Teduglutide

The significance of this substitution is that teduglutide is longer acting than endogenous GLP-2 as it is more resistant to proteolysis from dipeptidyl peptidase-4. FDA approved on December 21, 2012. … It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology.

Autologous cultured chondrocytes

It has been used since 1995 as Carticel and gained biologic license in 1997. The surgical implantation was first performed in Sweden. … It serves as an alternative repair treatment for patients with inadequate response to pre-existing surgical methods.

Metyrapone

An inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome.

Hydrocortisone cypionate

Hydrocortisone valerate

Tebentafusp

[L39995] Tebentafusp was subsequently approved for the same indication in the EU in April 2022.[L41675] … [L39995] It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunotherapy with a novel mechanism

Molnupiravir

[L39050] Molnupiravir was also granted emergency use authorization by the FDA on December 23, 2021; however, it is not yet fully approved.[L39588] … [A193014,A193026] With improved oral bioavailability in non-human primates, it is hydrolyzed _in vivo_, and distributes into tissues where it becomes the active 5’-triphosphate form.